Evidence map›Paper›PMID 27539537›Full record

ArticleBritish journal of haematology2016

Substance P and sickle cell disease-a marker for pain and novel therapeutic approaches.

Steven D Douglas

Registry-linked trialAbstract readEditorialComment
In one paragraph

Article in British journal of haematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04006639 (Comparison of Efficacy Between Bilateral Superficial Cervical Plexus Block and Local Infiltration of Lidocaine 2% in Patients Undergoing Tracheostomy), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04006639 nacompletednot on this mapstarted 2019, after this paper: background citation

Comparison of Efficacy Between Bilateral Superficial Cervical Plexus Block and Local Infiltration of Lidocaine 2% in Patients Undergoing Tracheostomy

TypeinterventionalSponsorIndonesia UniversityRan2019 to 2019Enrolled36ConditionsTracheostomyArmsAnalgesic Technique
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Steven D DouglasDepartment of Pediatrics, Division of Allergy and Immunology, Children's Hospital of Philadelphia Research Institute, Perelman School of Medicine, University of Pennsylvania, Abramson Research Center, Philadelphia, PA, USA. douglas@email.chop.edu.

Funding

Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6M
Penn Mental Health AIDS Research CenterP30MH097488 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI Knashawn Hodge Morales · 2013 to 2026
$23.5M
Substance P and NK1R Antagonists in Simian AIDSP01MH076388 · NIMH · CHILDREN'S HOSP OF PHILADELPHIA · PI HO, WENZHE · 2005 to 2008
$6.5M
TACHYKININS, MONONUCLEAR PHAGOCYTES, AND HIV1 INFECTIONR01MH049981 · NIMH · CHILDREN'S HOSP OF PHILADELPHIA · PI DOUGLAS, STEVEN DANIEL · 1995 to 2012
$5.8M
Project 5U01MH090325 · NIMH · CHILDREN'S HOSP OF PHILADELPHIA · PI DOUGLAS, STEVEN DANIEL · 2009 to 2013
$5.6M
Project 3: Targeting Neurokinin 1 ReceptorP01MH105303 · NIMH · TEMPLE UNIV OF THE COMMONWEALTH · PI DOUGLAS, STEVEN DANIEL, FISCHER, TRACY · 2014 to 2017
$4.3M
CD163 in HIV ImmunopathogenesisR21AI108296 · NIAID · CHILDREN'S HOSP OF PHILADELPHIA · PI DOUGLAS, STEVEN DANIEL · 2013 to 2014
$446k
NIAID NIH HHS P30 AI045008NIAID NIH HHS R21 AI108296NIMH NIH HHS P01 MH076388NIMH NIH HHS P01 MH105303NIMH NIH HHS P30 MH097488NIMH NIH HHS R01 MH049981NIMH NIH HHS U01 MH090325
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MorpholinesSubstance PAnemia, Sickle CellBiomarkersHumansPainBiomarkersMorpholinesSubstance Paprepitantneurokinin 1 antagonistpainsickle cell diseasesubstance P

Identifiers

PMID27539537
PMCPMC5063693

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.